AN OTSUKA MEDICAL DEVICES COMPANY

Press Release

02 Sept 2020

Veryan Medical (Horsham, UK) has announced that Dr. Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. The BioMimics 3D self-expanding, nitinol stent features a highly differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up, MIMICS-2.

Dr Wiechmann commented "We are thrilled to have the opportunity to implant the first BioMimics 3D stent in the U.S. in anticipation of the full commercial launch. The three-dimensional, helical design is unique in this stent category and has demonstrated promising results, as evidenced by the recent release of the 3 year follow up from the IDE pivotal study. The femoropopliteal segment still represents a significant challenge in the treatment of patients with peripheral artery disease, driven by a concern for long term durability and improved efficacy. We are excited to be able to offer this unique stent as part of our treatment algorithm to help address these challenges."

Nick Yeo, Veryan's CEO said, "We are delighted that Dr Wiechmann, a noted thought leader in the treatment of patients with PAD, has implanted the first BioMimics 3D stent in the US. Veryan believes that the combination of BioMimics 3D's compelling clinical results and its ease of use will be very attractive to US physicians many of whom have already given very positive feedback. We are confident that US physicians will see BioMimics 3D as an important addition to their treatment options for femoropopliteal disease."

BioMimics 3D Vascular Stent System

The BioMimics 3D stent has a unique 3-dimensional helical shape, designed to impart natural curvature to the diseased femoropopliteal artery, promoting swirling flow and elevating wall shear, which has been proven to have a protective effect on the endothelium.[1] The helical shape of the BioMimics 3D stent is also designed to facilitate shortening of the stented segment during knee flexion and mitigate the risk of stented segment compression causing localised strains that in a straight stent may lead to stent fracture and chronic vascular injury.[2,3]



About Veryan Medical
Veryan became an Otsuka Medical Devices company in December 2018 and applies design intelligence to create medical devices for vascular intervention that improve patient care through a combination of imagination, intuition and innovation. Veryan has offices in Horsham, UK, and Galway, Ireland, the location of the Veryan Innovation Centre that houses the Company's R&D activities. Veryan has direct sales teams in Germany and the US and has appointed distributors in other markets.

The BioMimics 3D Vascular Stent System has Premarket Approval in US and Japan and CE Mark approval in Europe. BioMimics 3D and Swirling Flow are registered trademarks of Veryan Medical Ltd.

For more information:
www.veryanmed.com
Vanessa Lee, Marketing Director
Vanessa.lee@veryanmed.com

References
1. Caro et al. 2013 J R Soc Interface 10: 20130578
2. BH Smouse et al, Endovasc. Today, vol 4, no. 6, pp. 60-66, 2005
3. Scheinert D et al, J Am Coll Cardiol 2005;45:312-5